LUS009 / Qilu Pharma - LARVOL DELTA

LUS009, a proprietary and potent VAV1 molecular glue degrader, inhibits both T and B cell functions and demonstrates strong efficacy in mouse models of colitis with good safety profile (ACR Convergence 2026) - "LUS009 is a highly potent and orally bioavailable molecular glue degrader that specifically targets and degrades VAV1 and blocks T cell functions, with strong potential as an oral therapy for alleviating IBD symptoms. Notably, LUS009 also ameliorates disease manifestations in multiple other auto-immune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and others."

IO biomarker • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Lupus • Rheumatoid Arthritis • Systemic Lupus Erythematosus • Targeted Protein Degradation • CD69 • VAV1